CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...